戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              CIDP with diabetes appears similar to CIDP without diabe
2                                              CIDP with diabetes appears to present older and more fre
3                                              CIDP with diabetes occurred later in life than CIDP with
4 utcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason
5                    Our results, both for all CIDP and typical CIDP presentations, support a twofold i
6  patients with IgM monoclonal antibodies and CIDP reacted to an epitope spanning aa 301-314 of beta-t
7 f serum peripherin and NfL levels in GBS and CIDP patients were not significantly associated with cli
8 f the immune attack in patients with GBS and CIDP.
9 icipate in the pathologic process of GBS and CIDP.
10               In Guillain-Barre syndrome and CIDP intravenous immunoglobulin is equivalent to but mor
11 his study, the largest reported trial of any CIDP treatment, shows the short-term and long-term effic
12 ncern for the clinician when misdiagnosed as CIDP, in view of the therapeutic implications.
13                      Diabetes was present at CIDP diagnosis in 25/139 (18%) subjects in the Serbian c
14                 IR-CAP could well be 'axonal CIDP' in view of clinical similarity, but not proven as
15  pg/ml), but NfL did not distinguish between CIDP (17.3 pg/ml), multiple sclerosis (21.5 pg/ml) and d
16 mmatory demyelinating polyneuropathy (CIDP), CIDP associated with human immunodeficiency virus infect
17                 Of these, 17 (71%) developed CIDP during the first pregnancy, and 8 (47%) had a relap
18 e we will discuss the pitfalls in diagnosing CIDP and the value of newly introduced diagnostic tests
19 eflect the different pathophysiology of each CIDP subtype.
20           Recent trials for other agents for CIDP treatment have not proved as promising, with a larg
21  and specificity of new EAN/PNS criteria for CIDP is equivalent to that of previous versions.
22  (EFNS/PNS) definite diagnostic criteria for CIDP.
23 al Fc receptor inhibitor rozanolixizumab for CIDP management.
24        None of the findings are specific for CIDP, meaning that the results of the diagnostic tests s
25 hese demyelinating findings are specific for CIDP.
26  and individualised treatment strategies for CIDP.
27  and supports use of IGIV-C as a therapy for CIDP.
28 g can be used as a maintenance treatment for CIDP.
29 the use of IVIG (Gamunex) as a treatment for CIDP.
30                    First-line treatments for CIDP, such as corticosteroids, immunoglobulin and plasma
31 ecificity was of 94% for 'CIDP' and 79% for 'CIDP' or 'possible CIDP'.
32                  Specificity was of 94% for 'CIDP' and 79% for 'CIDP' or 'possible CIDP'.
33     The sensitivity of EAN/PNS criteria for 'CIDP' was 83.3%.
34                         The sensitivity for 'CIDP' or 'possible CIDP' was 93.3%.
35 ssays, we showed that the IgGs from the four CIDP patients prevented adhesive interaction between con
36 tributes that might differentiate POEMS from CIDP and lead to earlier therapeutic intervention were e
37 cificity of 77% in discriminating POEMS from CIDP.
38 e was a striking synchronization between her CIDP and vestibulopathy with respect to clinical course
39                     However, in CIDP and HIV-CIDP, but not the other diseases, there was prominent up
40  human immunodeficiency virus infection (HIV-CIDP), IgM paraproteinaemic neuropathy and normal or non
41                                           In CIDP, periaxin discriminates patients with active diseas
42    Corticosteroid treatment is beneficial in CIDP, but not in Guillain-Barre syndrome and may worsen
43 ling key pathogenic mechanisms of disease in CIDP, followed by an in-depth description of potential n
44                                  However, in CIDP and HIV-CIDP, but not the other diseases, there was
45 eases, with significantly elevated levels in CIDP, GBS and CMT, but not in CNS disease or healthy con
46  that these ligands were upregulated only in CIDP.
47  with the Medical Research Council scale, in CIDP (rho=0.88, p<0.001) and also in CMT1A (rho=0.50, p<
48 A-DR antigen, the findings indicate that, in CIDP, Schwann cells possess the necessary markers to fun
49 and the heterogeneous response to therapy in CIDP.
50       Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditur
51       Treatment associated with an incorrect CIDP diagnosis led to total wasted healthcare expenditur
52  to estimate costs associated with incorrect CIDP diagnoses across our cohort.
53            138 POEMS patients and 69 matched CIDP controls were compared.
54 from 1960 to 2007 were compared with matched CIDP controls.
55                    Demyelinating neuropathy (CIDP or MMN) occurred in close to 30% of the patients, i
56 articular disease categories: Type J, 60% of CIDP cases; Type K, 75% of amyloid cases; Type L, 75% of
57 patients's relapsing and remitting course of CIDP and vestibulopathy was assessed by quantitative mus
58 h diabetes, although definitive diagnosis of CIDP is often challenging in the setting of concurrent d
59 umoral immune systems in the pathogenesis of CIDP will be discussed.
60 tion) along the nerve where the pathology of CIDP is probably predominantly proximal and distal.
61                We examined the reactivity of CIDP patients' sera against neuronal antigens and used i
62                      The onset or relapse of CIDP during pregnancy is a rare but challenging constell
63 paranodes may participate in the severity of CIDP.
64         According to the clinical subtype of CIDP, typical CIDP patients showed symmetric and root-do
65                  While the abiding theory of CIDP pathogenesis is that cell-mediated and humoral mech
66 s immunoglobulin (IVIG) for the treatment of CIDP and the US Food and Drug Administration approved th
67 ch is to our knowledge, the largest trial of CIDP to date and the first to study two administrations
68 iously been investigated in a large trial of CIDP.
69 opathy; however, the effects of pregnancy on CIDP have never been investigated except case reports or
70 .3% (1/23) in a German cohort of acute-onset CIDP.
71                                     No other CIDP patient or any of the 104 controls with other neuro
72 1 antibodies was 1.9% (1/52) in the Sant Pau CIDP cohort, and 4.3% (1/23) in a German cohort of acute
73 c inflammatory demyelinating polyneuropathy (CIDP) and diabetes is uncertain despite important diagno
74 c inflammatory demyelinating polyneuropathy (CIDP) and Guillain Barre syndrome (GBS), result from aut
75 c inflammatory demyelinating polyneuropathy (CIDP) are conditions that affect peripheral nerves.
76 c inflammatory demyelinating polyneuropathy (CIDP) except 'motor neuropathy subtype'.
77 c inflammatory demyelinating polyneuropathy (CIDP) has occasionally been associated with clinical or
78 c inflammatory demyelinating polyneuropathy (CIDP) in patients with diabetes, although definitive dia
79 c inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy typically charact
80 c inflammatory demyelinating polyneuropathy (CIDP) is rare but the most common chronic immune-mediate
81 c inflammatory demyelinating polyneuropathy (CIDP) is unknown.
82 c inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin.
83 c inflammatory demyelinating polyneuropathy (CIDP) were compared with 10 healthy subjects.
84 c inflammatory demyelinating polyneuropathy (CIDP), CIDP associated with human immunodeficiency virus
85 c inflammatory demyelinating polyneuropathy (CIDP), magnetic resonance neurography with 3-dimensional
86 c inflammatory demyelinating polyneuropathy (CIDP).
87 c inflammatory demyelinating polyneuropathy (CIDP).
88 c inflammatory demyelinating polyneuropathy (CIDP).
89 c inflammatory demyelinating polyneuropathy (CIDP).
90 c inflammatory demyelinating polyneuropathy (CIDP).
91 c inflammatory demyelinating polyneuropathy (CIDP).
92 matory demyelinating polyradiculoneuropathy (CIDP) and antibodies directed against the paranodal prot
93 matory demyelinating polyradiculoneuropathy (CIDP) and Guillain-Barre syndrome (GBS), the most common
94 matory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy with conduction bl
95 matory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown.
96 matory demyelinating polyradiculoneuropathy (CIDP) consists of a spectrum of autoimmune diseases of t
97 matory demyelinating polyradiculoneuropathy (CIDP) is a frequent autoimmune neuropathy with a heterog
98 matory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but clinically well-described d
99 matory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by we
100 matory demyelinating polyradiculoneuropathy (CIDP) is a rare and heterogeneous but treatable immune-m
101 matory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous
102 matory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory neuropathy, classically charact
103 matory demyelinating polyradiculoneuropathy (CIDP) shows autoantibodies to contactin (1).
104 matory demyelinating polyradiculoneuropathy (CIDP), as well as have an aggressive and rapidly disabli
105 matory demyelinating polyradiculoneuropathy (CIDP), will be discussed.
106 matory demyelinating polyradiculoneuropathy (CIDP).
107 matory demyelinating polyradiculoneuropathy (CIDP).
108 matory demyelinating polyradiculoneuropathy (CIDP, n = 35, 70 time points), multiple sclerosis (n = 3
109 matory demyelinating polyradiculoneuropathy (CIDP: N=20); amyloid polyneuropathy (N=20); intraneural
110      The sensitivity for 'CIDP' or 'possible CIDP' was 93.3%.
111 % for 'CIDP' and 79% for 'CIDP' or 'possible CIDP'.
112 %, p=0.38, respectively; 'CIDP' or 'possible CIDP': sensitivity: 93.3% vs 96.7%, p=0.25 and specifici
113             Adults with definite or probable CIDP receiving subcutaneous or intravenous immunoglobuli
114             Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatme
115 g 257 patients with 'definite' or 'probable' CIDP, from Serbia and Birmingham, UK.
116                 Despite its relative rarity, CIDP represents a significant economic burden, mostly du
117  change during stage A and their most recent CIDP medication within 6 months before screening.
118 ficity: 94% vs 96.1%, p=0.38, respectively; 'CIDP' or 'possible CIDP': sensitivity: 93.3% vs 96.7%, p
119 ents with a clinical diagnosis of 'suspected CIDP' and objective treatment response, attending Univer
120 DP with diabetes occurred later in life than CIDP without diabetes (58.96 years, SD: 11.09 vs 51.71 y
121 re many phenotypic variants, suggesting that CIDP may not be a discrete disease entity but rather a s
122 clusion of paranodopathies and CISP from the CIDP spectrum impacts on management of a non-negligible
123        'Typical CIDP' represented 79% of the CIDP cohort.
124              Of the 17 patients, in whom the CIDP subtypes were determined, all of them had typical C
125  and constitute a single subgroup within the CIDP syndrome.
126 relationship of cranial nerve involvement to CIDP remains unclear.
127        CIDP with diabetes appears similar to CIDP without diabetes in disability levels at diagnosis
128                                     'Typical CIDP' represented 79% of the CIDP cohort.
129   Our results, both for all CIDP and typical CIDP presentations, support a twofold increased relative
130 ing to the clinical subtype of CIDP, typical CIDP patients showed symmetric and root-dominant hypertr
131                          Considering typical CIDP only, diabetes prevalence was greater than expected
132 pes were determined, all of them had typical CIDP.
133 e suggest that pregnancy can trigger typical CIDP in some women, and women with CIDP have a higher ri
134 l as well as distal muscle weakness (typical CIDP).
135                              Whereas typical CIDP is relatively easy to diagnose, atypical variants w
136  41.5(10.6) p.u. (CMT1A) and 39.3(8.7) p.u. (CIDP).
137        The largest component of the 'variant CIDP' group was represented by focal/multifocal forms (1
138 es were ascertained with previous versions ('CIDP': sensitivity: 83.3% vs 81.3%, p=0.74, specificity:
139 ubcutaneous efgartigimod PH20 in adults with CIDP.
140                                Compared with CIDP controls, POEMS patients demonstrated: (1) greater
141 uently in the typical form, as compared with CIDP without diabetes.
142                                Compared with CIDP, there is greater axonal loss (reduction of motor a
143 controlled trial, enrolled participants with CIDP from 146 clinical sites from Asia-Pacific, Europe,
144  to measure plasma periaxin in patients with CIDP (n = 45, including longitudinal samples across a di
145 zumab did not show efficacy in patients with CIDP in this study, although this could be due to a rela
146           Four of 46 sera from patients with CIDP reacted strongly against hippocampal neurons (8.6%)
147 sting, we identified sera from patients with CIDP showing strong membrane reactivity when both CNTN1
148                            117 patients with CIDP who met specific neurophysiological inflammatory ne
149 1 complex occur in a subset of patients with CIDP who share common clinical features.
150 lemtuzumab) showing benefit in patients with CIDP, but the side effect profiles can be worrisome.
151 plex have been reported in few patients with CIDP.
152 -term and long-term benefit in patients with CIDP.
153 are found in about one-half of patients with CIDP.
154 isk of relapse versus placebo in people with CIDP who responded to treatment.
155 r typical CIDP in some women, and women with CIDP have a higher risk of relapse during pregnancy.
156  to 30 June 2020 that revealed 24 women with CIDP, who had onset or relapse during pregnancy.

 
Page Top